BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 25535952)

  • 1. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
    Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
    Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
    Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
    Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.
    Halder AK; Saha A; Jha T
    J Pharm Pharmacol; 2013 Oct; 65(10):1541-54. PubMed ID: 24028622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
    Aboalhaija NH; Zihlif MA; Taha MO
    Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
    Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
    J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QSAR models for isoindolinone-based p53-MDM2 interaction inhibitors using linear and non-linear statistical methods.
    Dong X; Yan J; Lu D; Wu P; Gao J; Liu T; Yang B; Hu Y
    Chem Biol Drug Des; 2012 May; 79(5):691-702. PubMed ID: 22233482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
    Tian Y; Lahue BR; Ma Y; Nair LG; Pan W; Doll RJ; Guzi T; Ma Y; Wang Y; Bogen SL
    Bioorg Med Chem Lett; 2022 Apr; 61():128625. PubMed ID: 35158044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
    Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
    Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energy-Based Pharmacophore and Three-Dimensional Quantitative Structure--Activity Relationship (3D-QSAR) Modeling Combined with Virtual Screening To Identify Novel Small-Molecule Inhibitors of Silent Mating-Type Information Regulation 2 Homologue 1 (SIRT1).
    Pulla VK; Sriram DS; Viswanadha S; Sriram D; Yogeeswari P
    J Chem Inf Model; 2016 Jan; 56(1):173-87. PubMed ID: 26636371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
    Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
    Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
    J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
    Kumar R; Son M; Bavi R; Lee Y; Park C; Arulalapperumal V; Cao GP; Kim HH; Suh JK; Kim YS; Kwon YJ; Lee KW
    Acta Pharmacol Sin; 2015 Aug; 36(8):998-1012. PubMed ID: 26051108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
    Tian Y; Ma Y; Gibeau CR; Lahue BR; Shipps GW; Strickland C; Bogen SL
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2735-8. PubMed ID: 27080185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.